Prasugrel, a New Platelet Inhibitor
Authors:
- 20 May 2010
- journal article
- Published by Wiley in Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
- Vol. 77 (3) , 315-323
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: A TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)–Thrombolysis in Myocardial Infarction (TIMI) 38 SubstudyAmerican Heart Journal, 2009
- Antithrombotic Therapy for Non–ST-Segment Elevation Acute Coronary SyndromesChest, 2008
- Acute ST-Segment Elevation Myocardial InfarctionChest, 2008
- The active metabolite of prasugrel effectively blocks the platelet P2Y12receptor and inhibits procoagulant and pro-inflammatory platelet responsesPlatelets, 2008
- Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary InterventionCirculation, 2007
- Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseEuropean Heart Journal, 2007
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseEuropean Heart Journal, 2006
- A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary SyndromesJACC, 2006
- Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y 12 Antagonist, With Clopidogrel in Percutaneous Coronary InterventionCirculation, 2005